TR200501460T3 - Onkolitik virüsler kullanarak ağrı azaltma yöntemi - Google Patents

Onkolitik virüsler kullanarak ağrı azaltma yöntemi

Info

Publication number
TR200501460T3
TR200501460T3 TR2005/01460T TR200501460T TR200501460T3 TR 200501460 T3 TR200501460 T3 TR 200501460T3 TR 2005/01460 T TR2005/01460 T TR 2005/01460T TR 200501460 T TR200501460 T TR 200501460T TR 200501460 T3 TR200501460 T3 TR 200501460T3
Authority
TR
Turkey
Prior art keywords
mammal
oncolytic viruses
reduction method
pain reduction
oncolytic
Prior art date
Application number
TR2005/01460T
Other languages
English (en)
Turkish (tr)
Inventor
Morris Donald
C. Coffey Matthew
G. Thompson Bradley
Original Assignee
Oncolytics Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech, Inc. filed Critical Oncolytics Biotech, Inc.
Publication of TR200501460T3 publication Critical patent/TR200501460T3/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/765Reovirus; Rotavirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2005/01460T 2002-05-09 2003-05-07 Onkolitik virüsler kullanarak ağrı azaltma yöntemi TR200501460T3 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37867502P 2002-05-09 2002-05-09
US44317703P 2003-01-29 2003-01-29

Publications (1)

Publication Number Publication Date
TR200501460T3 true TR200501460T3 (tr) 2005-06-21

Family

ID=29423642

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2005/01460T TR200501460T3 (tr) 2002-05-09 2003-05-07 Onkolitik virüsler kullanarak ağrı azaltma yöntemi

Country Status (19)

Country Link
US (2) US20040091458A1 (enExample)
EP (1) EP1505992B1 (enExample)
JP (1) JP5241059B2 (enExample)
AR (1) AR039986A1 (enExample)
AT (1) ATE404213T1 (enExample)
AU (1) AU2003229431B8 (enExample)
BR (1) BR0309825A (enExample)
CA (1) CA2484398C (enExample)
DE (2) DE03722131T1 (enExample)
DK (1) DK1505992T3 (enExample)
ES (1) ES2239928T3 (enExample)
IL (1) IL164695A (enExample)
MX (1) MXPA04011007A (enExample)
NZ (1) NZ536102A (enExample)
PT (1) PT1505992E (enExample)
SI (1) SI1505992T1 (enExample)
TR (1) TR200501460T3 (enExample)
TW (1) TWI316405B (enExample)
WO (1) WO2003094938A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
KR20100054358A (ko) * 2008-11-14 2010-05-25 김재은 스틱 연고
AU2010242748B2 (en) * 2009-05-01 2015-07-23 Adare Pharmaceuticals, Inc. Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
EP2383577A1 (en) * 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
CA2990133A1 (en) 2015-06-19 2017-03-09 Sillajen, Inc. Compositions and methods for viral embolization
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
NZ518945A (en) * 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Also Published As

Publication number Publication date
EP1505992A1 (en) 2005-02-16
NZ536102A (en) 2008-01-31
BR0309825A (pt) 2005-03-01
CA2484398C (en) 2014-01-21
DE03722131T1 (de) 2005-09-15
ATE404213T1 (de) 2008-08-15
AU2003229431B8 (en) 2009-07-02
AU2003229431A1 (en) 2003-11-11
US20040091458A1 (en) 2004-05-13
EP1505992B1 (en) 2008-08-13
JP2005526124A (ja) 2005-09-02
PT1505992E (pt) 2008-10-06
AR039986A1 (es) 2005-03-09
WO2003094938A1 (en) 2003-11-20
DE60322885D1 (de) 2008-09-25
ES2239928T1 (es) 2005-10-16
IL164695A0 (en) 2005-12-18
IL164695A (en) 2010-12-30
SI1505992T1 (sl) 2009-02-28
HK1070565A1 (en) 2005-06-24
TW200402305A (en) 2004-02-16
JP5241059B2 (ja) 2013-07-17
CA2484398A1 (en) 2003-11-20
AU2003229431B2 (en) 2008-01-17
TWI316405B (en) 2009-11-01
DK1505992T3 (da) 2008-10-06
US20080081032A1 (en) 2008-04-03
ES2239928T3 (es) 2009-02-16
MXPA04011007A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
TR200501460T3 (tr) Onkolitik virüsler kullanarak ağrı azaltma yöntemi
EA201790882A1 (ru) Способы и композиции для терапии рака печени
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
AR059482A1 (es) Uso de supresion inmune local para potenciar terapia viral oncolitica
AR032912A1 (es) Formulacion farmaceutica
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
NO20054988D0 (no) Preparater og metoder for behandling av cancer
PL371736A1 (en) Method for administering glp-1 molecules
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
NZ589719A (en) Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
PT933993E (pt) Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
BRPI0509177A (pt) uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas
NO20051654L (no) Forlenget frigjoring av farmasoytisk preparat
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
EA200200502A1 (ru) Способ введения ингибитора фосфодиэстеразы 4
DE69533873D1 (de) Krebstherapie mit lymphotoxin
EA201101036A1 (ru) Применение хлорида аммония в терапии
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
BRPI0607084A2 (pt) uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto